Palliative Care and Endocrine Diseases
Palliative care in endocrine diseases is similar to palliative care in any other disease. The aim will be to reduce the symptoms, avoid short-term complications and improve or maintain the quality of life by minimal interference and with least inconvenience to the patient. Palliative care in diabetes mellitus aims at avoiding hypoglycemia and symptomatic hyperglycemia, and not necessarily achieving euglycemia or postponing/preventing chronic complications of diabetes. Palliative care in thyroid disorders aims to help the patient remain asymptomatic in both hypothyroidism and hyperthyroidism and not normalizing the TSH. Palliative care in all other endocrine diseases like Cushing’s disease, pheochromocytoma, pituitary tumor, insulinoma, and hyperparathyroidism is also mostly minimal medical intervention to alleviate symptoms and improve quality of life. Replacing endocrine deficiency as in Addisons disease, hypothyroidism, hypocalcemia due to hypoparathyroidism is important and similarly managed to any other endocrine deficiency.
- End of life Diabetes care. Clinical care recommendations 2nd ed. 2013.Google Scholar
- Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, Cooper S, Kim W, Peeters P, Rosenthal MS, Sawka AM. Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24(12):1670–751.CrossRefGoogle Scholar
- Ross DS, Burch B, Cooper David S, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343–421.CrossRefGoogle Scholar
- Takats KI, Szabolcs I, Foldes J, Foldes I, Ferencz A, Rimanoczy E, Goth M, Dohan O, Kovacs L, Szilagyi G. The efficacy of long term thyrostatic treatment in elderly patients with toxic nodular goitre compared to radioiodine therapy with different doses. Exp Clin Endocrinol Diabetes. 1999;107:70–4.CrossRefGoogle Scholar